News

An appellate panel has stayed the nationwide injunction issued by a federal judge in Texas that halted enforcement of the Corporate Transparency Act (CTA). Hours later, the U.S.

In Notice 2024-73, the Internal Revenue Service (“IRS”) issued guidance on the application of certain non-discrimination rules to long-term, part-time employees in Internal Revenue Code (“Code”) Section 403(b) plans subject to ERISA (“ERISA LTPT employees”).

This client alert is a follow-up on our prior client alerts related to reporting requirements under the Corporate Transparency Act (“CTA”). In our last client alert on the CTA, we informed you that on December 3, 2024, the U.S.

December 23, 2024- In view of the evolving legal landscape, the Board of Governors of the Federal Reserve System announced it will soon seek public comment on significant changes to improve the transparency of its bank stress tests and to reduce the volatility of resulting capital buffer requir

On December 23, 2024, the United States Court of Appeals for the Fifth Circuit issued an order granting the Department of Justice’s emergency motion for a stay pending appeal, lifting the nationwide injunction blocking the government from enforcing the reporting requirements of the Corporate Tran

When I investigated and litigated False Claims Act (FCA) cases at the U.S. Department of Justice (DOJ) over the last 10 years, I was often surprised by just how little I knew about the broad array of government agencies and the intricacies of how those agencies’ various programs work.

On December 23, the U.S. Court of Appeals for the Fifth Circuit issued an Order staying the nationwide injunction that previously halted the enforcement of the Corporate Transparency Act (the “CTA”).

On December 23, the Fifth Circuit Court of Appeals lifted the stay on the Corporate Transparency Act (CTA), reinstating its enforcement nationwide. The CTA requires certain non-exempt entities to report the identities of their beneficial owners to the U.S.

On December 20th, 2024, the Court of Appeals for the Federal Circuit issued an important decision in Teva Branded Pharmaceutical Products R&D v. Amneal Pharmaceuticals that impacts Orange Book (OB) listings for patents related to FDA-approved drug/device combination products.

This Alert covers updates from the Financial Crimes Enforcement Network (FinCEN) regarding Corporate Transparency Act (CTA) beneficial ownership information (BOI) reporting requirements resuming.

Pages